The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Open accessAbstract
Summary Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of metformin’s role in cancer immunity are not fully understood. Here we show metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1). Furthermore, we discover that AMP-activated protein kinase (AMPK) activated by metformin directly phosphorylates S195 of PD-L1. S195 phosphorylation induces abnormal PD-L1 glycosylation, resulting in its ER accumulation and ER-associated degradation (ERAD). Consistently, tumor tissues from metformin-treated breast cancer patients exhibit reduced PD-L1 levels with AMPK activation. Blocking the inhibitory signal of PD-L1 by metformin enhances CTL activity against cancer cells. Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 12×
“Together, these data suggested that S195-P by metformin prevents the translocation of PD-L1 to the cell membrane and subsequent PD-1 binding, and therefore, increasing the activity of CTL. Phosphorylation of S195 induces ER-associated degradation of PD-L1 The above findings indicated that PD-L1 S195-p induces a mannos…”
BackgroundInfluentialWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
One step at a time: endoplasmic reticulum-associated degradation
Vembar, S. S., & Brodsky, J. L. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2546 · Cited by 1,299
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Self-citationManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
Hardie, D. G., Schaffer, B. E., & Brunet, A. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.013 · Cited by 859
Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation
Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.001 · Cited by 773
Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death
Chowdhury, D., & Lieberman, J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090404 · Cited by 700
Effect of glycosylation on protein folding: A close look at thermodynamic stabilization
Shental-Bechor, D., & Levy, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801340105 · Cited by 618
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520
Glycosylation-directed quality control of protein folding
Xu, C., & Ng, D. T. W. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4073 · Cited by 414
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
COPII and the regulation of protein sorting in mammals
Zanetti, G., Pahuja, K. B., Studer, S., Shim, S., & Schekman, R. (2012) · Nature Cell Biology · doi:10.1038/ncb2390 · Cited by 378
N-Linked Protein Glycosylation in the Endoplasmic Reticulum
Breitling, J., & Aebi, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013359 · Cited by 332
Adaptive immune activation: glycosylation does matter
Wolfert, M. A., & Boons, G.-J. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1403 · Cited by 327
Hadad, S., Iwamoto, T., Jordan, L., Purdie, C., Bray, S., Baker, L., Jellema, G., Deharo, S., Hardie, D. G., Pusztai, L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1612-1 · Cited by 293
Self-citationIRE1α is an endogenous substrate of endoplasmic-reticulum-associated degradation
Sun, S., Shi, G., Sha, H., Ji, Y., Han, X., Shu, X., Ma, H., Inoue, T., Gao, B., Kim, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3266 · Cited by 253
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 224
Satelli, A., Batth, I. S., Brownlee, Z., Rojas, C., Meng, Q. H., Kopetz, S., & Li, S. (2016) · Scientific Reports · doi:10.1038/srep28910 · Cited by 203
Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016) · Medicine · doi:10.1097/md.0000000000004614 · Cited by 201
Role of N-glycosylation in trafficking of apical membrane proteins in epithelia
Vagin, O., Kraut, J. A., & Sachs, G. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90340.2008 · Cited by 198
Qi, J., Gong, J., Zhao, T., Zhao, J., Lam, P., Ye, J., Li, J. Z., Wu, J., Zhou, H., & Li, P. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.92 · Cited by 164
Regulation of Endoplasmic Reticulum-Associated Protein Degradation (ERAD) by Ubiquitin
Lemus, L., & Goder, V. (2014) · Cells · doi:10.3390/cells3030824 · Cited by 130
Compartmentalized AMPK Signaling Illuminated by Genetically Encoded Molecular Sensors and Actuators
Miyamoto, T., Rho, E., Sample, V., Akano, H., Magari, M., Ueno, T., Gorshkov, K., Chen, M., Tokumitsu, H., Zhang, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.057 · Cited by 117
AMP-activated protein kinase and human cancer: cancer metabolism revisited
Kuhajda, F. P. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.121 · Cited by 105
Hadad, S. M., Coates, P. J., Jordan, L. B., Dowling, R. J. O., Chang, M. C., Done, S. J., Purdie, C. A., Goodwin, P. J., Stambolic, V., Moulder-Thompson, S. L., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3307-5 · Cited by 98
Self-citationGlycoprotein folding and quality-control mechanisms in protein-folding diseases
Ferris, S. P., Kodali, V. K., & Kaufman, R. J. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014589 · Cited by 97
Nishikawa, S., Hirata, A., & Nakano, A. (1994) · Molecular Biology of the Cell · doi:10.1091/mbc.5.10.1129 · Cited by 86
Zhao, D., Long, X., Lu, T., Wang, T., Zhang, W., Liu, Y. G., Cui, X., Dai, H., Xue, F., & Xia, Q. (2014) · International Journal of Cancer · doi:10.1002/ijc.29305 · Cited by 85
Metformin in breast cancer - an evolving mystery
Camacho, L., Dasgupta, A., & Jiralerspong, S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0598-8 · Cited by 62
Parra, K., Valenzuela, P., Lerma, N., Gallegos, A., Reza, L. C., Rodriguez, G., Emmenegger, U., Desidero, T. D., Bocci, G., Felder, M. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.429 · Cited by 51
Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I
van den Boomen, D. J. H., & Lehner, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.07.005 · Cited by 49
Coinhibitory Molecules in Autoimmune Diseases
Watanabe, N., & Nakajima, H. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/269756 · Cited by 45
Metformin: an old drug with new potential
Hajjar, J., Habra, M. A., & Naing, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.833604 · Cited by 42
Yagi, H., Kuo, C., Obayashi, T., Ninagawa, S., Khoo, K., & Kato, K. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.062729 · Cited by 40
Self-citationIpilimumab plus nivolumab for advanced melanoma
Hassel, J. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30409-0 · Cited by 35
Cited by
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Self-citationTargeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
Metadata
- Authors
- Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., Hsu, J. L., Wang, H.-L., Kuo, C.-W., Chang, W.-C., Hadad, S., Purdie, C. A., McCoy, A. M., Cai, S., Tu, Y., Litton, J. K., Mittendorf, E. A., Moulder, S. L., Symmans, W. F., Thompson, A. M., Piwnica-Worms, H., Chen, C.-H., Khoo, K.-H., & Hung, M.-C.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 71
- Issue
- 4
- Pages
- 606-620.e7
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2885288866
- Cited by
- 773
- References
- 50
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.